Gilead Sciences (GILD) Tops Q3 EPS by 94c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021 4:02 PM EDT2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter
Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021.
This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Veklury is making a significant impact as the COVID-19 pandemic continues... More
